Great Point Partners
Great Point Partners reported 37 stocks worth $424M in its 13F filing for Q2 2026, filed Aug 14, 2026. Its largest holdings are VOR (7.4%), ABVX (6.4%) and VERA (6.1%). Compared with Q1 2026, the fund opened new positions in ABVX, DFTX and SGMT, added to VERA, ANNX and MLTX, trimmed VOR, CLYM and AMLX and sold out of IMVT, JBIO and ZBIO.
Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 |  VOR Vor Biopharma Inc Com New | $31.3M | 7.4% | 1.7M | −50K (−3%) | 3 of 8 | |
| 2 |  ABVX Abivax SA | $27.2M | 6.4% | 204K | New position | 6 of 8 | |
| 3 |  VERA Vera Therapeutics Inc | $25.8M | 6.1% | 601K | +401K (+201%) | 2 of 8 | |
| 4 |  ZURA Zura Bio Ltd | $24.9M | 5.9% | 4.2M | No change | 8 of 8 | |
| 5 |  ALMS Alumis Inc | $24.1M | 5.7% | 856K | No change | 2 of 8 | |
| 6 |  SLGL Sol Gel Technologies | $20.3M | 4.8% | 274K | No change | 2 of 8 | |
| 7 |  DFTX Definium Therapeutics Inc | $20M | 4.7% | 425K | New position | 1 of 8 | |
| 8 |  ANNX Annexon Inc | $20M | 4.7% | 3.5M | +1M (+40%) | 2 of 8 | |
| 9 |  ORKA Oruka Therapeutics Inc | $17.4M | 4.1% | 183K | No change | 6 of 8 | |
| 10 |  MLTX Moonlake Immunotherapeutics | $16.7M | 3.9% | 856K | +356K (+71%) | 2 of 8 |
Positions at Jun 30, 2026, as reported. Change is against the fund's Q1 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q1 2026, gone in Q2 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
APOGEE THERAPEUTICS INC | $31.5M | 374K |
KALVISTA PHARMACEUTICALS INC | $13.6M | 675K |
 IMVT Immunovant Inc | $13.6M | 546K |
 JBIO Jade Biosciences Inc | $13.6M | 964K |
 ZBIO Zenas Biopharma Inc | $10.2M | 524K |
🔒 Free account: see all 13.
Options
valued at the underlying shares
Reported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q2 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Aug 14, 2026 | 13F-HR | Q2 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Great Point Partners 13F FAQ
What does Great Point Partners own?
Great Point Partners reported 37 stocks worth $424M in its 13F filing for Q2 2026, filed Aug 14, 2026. Its largest holdings are VOR (7.4%), ABVX (6.4%) and VERA (6.1%). The table above lists every position in the filing (the top 10 without an account).
What did Great Point Partners buy and sell in Q2 2026?
Compared with Q1 2026: 11 new positions, 7 added to, 9 trimmed and 13 sold out. New positions include ABVX, DFTX and SGMT. It sold all of IMVT, JBIO and ZBIO.
When will Great Point Partners file its next 13F?
Holdings as of Sep 30, 2026 are due by Nov 16, 2026. The filing appears on this page within minutes of reaching the SEC.
How much is Great Point Partners's portfolio worth?
The Q2 2026 filing reports $424M in US stocks ($529M including options). That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.